

Research article

Open Access

Long-term survival after initial hospital admission for peripheral arterial disease in the lower extremities

I Vaartjes*¹, GJ de Borst², JB Reitsma³, A de Bruin⁴, FL Moll², DE Grobbee¹ and ML Bots¹

Address: ¹Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands, ²Department of Vascular Surgery, University Medical Center Utrecht, Utrecht, the Netherlands, ³Department of Clinical Epidemiology and Biostatistics, Academic Medical Center, Amsterdam, the Netherlands and ⁴Statistics Netherlands, The Hague, the Netherlands

Email: I Vaartjes* - c.h.vaartjes@umcutrecht.nl; GJ de Borst - G.J.deBorst-2@umcutrecht.nl; JB Reitsma - J.Reitsma@amc.uva.nl; A de Bruin - abun@cbs.nl; FL Moll - F.L.Moll@umcutrecht.nl; DE Grobbee - D.E.Grobbee@umcutrecht.nl; ML Bots - M.L.Bots@umcutrecht.nl

* Corresponding author

Published: 28 August 2009

Received: 5 June 2009

BMC Cardiovascular Disorders 2009, **9**:43 doi:10.1186/1471-2261-9-43

Accepted: 28 August 2009

This article is available from: <http://www.biomedcentral.com/1471-2261/9/43>

© 2009 Vaartjes et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: As the population ages, peripheral arterial disease (PAD) in the lower extremities will become a larger public health problem. Awareness in patients as well clinicians of the high risk of morbidity and mortality is important but seems currently low. Insights in absolute mortality risks following admission for PAD in the lower extremities can be useful to improve awareness as they are easy to interpret.

Methods: A nationwide cohort of 4,158 patients with an initial admission for PAD in the lower extremities was identified through linkage of the national hospital and population register in 1997 and 2000.

Results: Over 60% of 4,158 patients were men. 28 days, 1 year and 5 year mortality risk were 2.4%, 10.3% and 31.0% for men and 3.5%, 10.4% and 27.4% for women. Coronary heart disease and stroke were frequent cause of death. Five years mortality risk was higher for men compared to women (HR 1.36, 95% CI 1.21–1.53).

Conclusion: In conclusion, our findings demonstrate that, 5 year mortality risk is high, especially in men and comparable to that of patients admitted for acute myocardial infarction or ischemic stroke. Though, in general population the awareness of the severity of PAD in the lower extremities is significantly lower than that for any other cardiovascular disease and it seems that cardiovascular risk factor management for prevention in PAD patients is very modest.

Background

Peripheral arterial disease (PAD) is a manifestation of atherosclerosis, affecting an estimated 27 million people in Europe and North America [1]. Intermittent claudication (IC) is the most common symptom of PAD in the lower extremities. IC has a severe impact on various

aspects of quality of life [2,3], on the ability to continue to work and approximately 15% to 20% of the patients with IC develop critical limb ischemia (CLI) [4,5]. Furthermore, patient with IC have an increased mortality risk compared to the general population [6,7].

Previous studies reported that individuals with PAD have a 20–60% increased risk for myocardial infarction, a two- to six-fold increased risk of cardiovascular death, and a 40% increased risk of stroke compared to those without PAD [5,8,9]. In spite of many publications reporting an increased risk of morbidity and mortality, patients with PAD lack knowledge regarding the risk of heart attack, stroke and total mortality [10]. Furthermore, the use of secondary prevention treatment in these patients have shown to be modest at best [11].

Although PAD in the lower extremities is rare among young individuals its prevalence increases dramatically with age [7,12]. As the population ages, PAD in the lower extremities will become a greater public health problem [7,12], leading to an increasing necessity for primary and secondary prevention. Awareness in patients as well clinicians of the high risk of morbidity and mortality is therefore important. Most available literature, including institutional and population-based studies, present overall mortality risks for patients with PAD in the lower extremities [13-17] or use relative risks or odds ratio's when reporting mortality [8,11,16]. However, absolute mortality risks stratified by age and gender may be more useful as absolute risks are easier to interpret and they provide a clearer presentation of the size of the burden of disease in these patients. We set out to study absolute mortality risk stratified by age and gender after first hospital admission for PAD in the lower extremities.

Methods

Registries and linkage procedure

To construct a cohort of patients admitted for the first time because of PAD in the lower extremities, information from the national Hospital Discharge Registry (HDR) and the Dutch Population Registry (PR) were linked. Information on cause of death was derived from the cause of death registry of Statistics Netherlands. The registries and linkage procedures have been described in detail previously for a cohort of acute myocardial infarction patients [18] and stroke [19]. In brief, the HDR is a nationwide database on admissions, not persons. For each hospital admission a new record is created in the HDR. Following individuals over time based on HDR-information alone is troublesome due to difficulties in identification of different admissions from the same person in time and admissions for the same condition at a different hospital (due to referral or to address changes). Yet, linkage (linkage variables date of birth, gender and 4 digits of postal code) with the PR may overcome these issues.

For the present study, cohorts were extracted from 1997 and 2000 because of pragmatic reasons at the time of the initiation of the project in 2001. The total population of the Netherlands in 1997 and 2000 was 15,567,107 (men

7,696,803, women 7,870,304) and 15,863,950 (men: 7,846,317, women: 8,017, 633), respectively.

Definition

PAD in the lower extremities was defined using the International Classification of Diseases, 9th Revision [20] code 4439. This code is described as peripheral vascular disease unspecified, intermittent claudication not otherwise specified (NOS). Peripheral: angiopathy NOS, vascular disease NOS, Spasm of artery. Excluded are atherosclerosis of the arteries of the extremities and spasm of cerebral artery.

The ICD code does not provide information on severity. We assume that patients with moderate-severe claudication, ischemic rest pain and ulceration or gangrene (Fontaine stage IIb, III and IV, respectively) are hospitalized as these patients have an indication for surgical interventions [3]

Study population

All hospital admissions for PAD in the lower extremities between January 1st and December 31st, 1997 and January 1st and December 31st, 2000, were selected from the national hospital discharge registry (which was previously linked with PR). There were 7,161 hospital admissions. Selection of the first admission for an individual of all subsequent admissions of a person occurring 1997 and 2000 yielded a total of 5,886 patients with PAD in the lower extremities. Subsequently, information was collected on hospital admission that may have occurred previously (1995–1997 (data earlier than 1995 not available since linkage with PR is only possible from 1995) and 1995–2000, respectively) for the same condition. Those with a previous admission for peripheral arterial disease were excluded (n = 1,728). This resulted in a cohort consisting of 4,158 patients with a first hospitalization for PAD in the lower extremities in 1997 or 2000 in the Netherlands.

Co-morbidity

The presence of co-morbidity (cardiovascular disease (ICD-9-CM codes 390–459) or diabetes mellitus (DM) (ICD-9-CM code 250)) was determined on the basis of the discharge diagnosis of previous hospital admissions or on the basis of a secondary diagnosis at the time of the index admission. No information in the registry was available on the severity of disease, risk factor (hypertension, smoking) or medication use.

Follow-up

Information on mortality was obtained by linkage of the cohort with national cause of death register. Linkage of the PR (which was linked previously to the HDR cohort) with the cause of death register was performed using an unique identification key and therefore was nearly com-

plete. Patients were censored if they migrated out of the Netherlands or if their linkage key was not unique anymore during follow-up. Causes of death were coded using the tenth revision of the International Classification of Disease (ICD-10) [21].

Data analysis

Survival time was calculated as the time from the initial admission date for IC in 1997 or 2000 to the date of death from any cause or to the date that a patient was censored, whichever came first. The crude short-term (28 day), 1 year and long-term (5-year) mortality were computed by age and gender according to the actuarial life table method and expressed as percentages. The mortality rate in men was compared to mortality rate in women by calculating relative risks (with 95% CI). Cox regression models were used to study differences between men and women in their risk of death. Mortality at 28-days, 1-year and 5-years was examined. For each period, a model was fitted to adjust for for age and co-morbidity (previous admissions for cardiovascular disease or DM). Data were analyzed with SPSS software, version 14.0 (SPSS Inc, Chicago, Illinois, USA). All analyzes were performed in agreement with privacy legislation in the Netherlands [22].

Results

A total of 4,158 patients with a first hospital admission for a PAD in the lower extremities in 1997 or 2000 were identified. General characteristics are provided in Table 1. Two

percent, 10% and 31% of all men and 4%, 10% and 27% of all women died within 28 days, 1-year and 5-years, respectively.

Cause of death

Cardiovascular diseases were the most frequent cause of death at 28-days, 1-year and 5-years (Table 2). The contribution of cardiovascular diseases as cause of death decreased over time while the contribution of cancer as a cause of death increased.

28-day mortality

Short term mortality risk increased with age in men and women (from 2.3% in men between 65–69 years to 18.4% in men older than 85 years and from 2.3% in women between 50–54 years to 18.8% in women older than 85 years) (Table 3). The crude overall mortality was lower for men (relative risk 0.67; 95% CI 0.47 to 0.96). After adjustment for potential confounding factors no differences between men and women in mortality were observed (Table 4).

One-year mortality

Mortality increased with age in men and women (from 1.8% in men younger than 45 years to 47.7% in men older than 85 years and from 3.9% in women between 50–54 years to 41.0% in women older than 85 years). A higher mortality in men compared with women was found across all ages above 55 years, however differences

Table 1: Characteristics of patients with a first hospitalization for PAD in the lower extremities in 1997 or 2000.

	Men	Women	Total
Number of patients	2,539	1,619	4,158
Age at admission (years)			
Mean	66.1	66.9	66.4
Standard deviation	11.6	13.9	12.6
Previous hospital admission in 1995–1997, 1995–2000 (%)			
cardiovascular disease	28.9*	25.0	27.3
- ischemic heart disease	13.6*	8.6	11.7
- acute myocardial infarction	3.7	3.2	3.5
- congestive heart failure	3.9	3.5	3.8
- stroke	4.6*	3.3	4.1
- other cardiovascular disease	14.0	15.2	14.5
diabetes mellitus	10.8	13.3*	11.8
Type of hospital (%)			
- academic	11.2*	7.8	9.9
Length of stay (days)			
Mean	4	5	4
Origin (%)			
-native	91.5	89.5	90.7

Table 2: Causes of death at 28-days, 1-year and 5-years of patients with a first hospitalization for PAD in the lower extremities in the Netherlands.

Cause of death	28 days		1-year		5-years	
	Men (n = 60)	Women (n = 57)	Men (n = 262)	Women (n = 168)	Men (n = 786)	Women (n = 443)
Cardiovascular diseases	70.0	68.4	55.0	61.9	50.3	53.7
- ischemic heart disease	23.3	12.3	14.5	15.5	17.4	14.7
- AMI	11.7	8.8	7.6	11.3	10.3	10.4
- congestive heart failure	5.0	7.0	5.7	6.5	4.8	4.7
- stroke	1.7	7.0	9.2	8.3	8.9	7.9
- peripheral arterial diseases	33.3	35.1	19.8	22.6	12.1	15.3
- other cardiovascular diseases	6.7	7.0	5.7	8.9	7.0	11.1
Cancer	5.0	1.8	13.7*	6.5	18.1	12.6
- lung cancer	3.3	0.0	5.7	2.4	6.9	3.8
Diseases of respiratory system	11.7	7.0	9.5	6.5	9.9	8.1
- COPD	5.0	5.3	5.0	3.6	5.2	3.8
Complications from DM	8.3	12.3	8.8	11.9	7.3	10.8
Other	5.0	10.5	13.0	13.2	14.4	14.8

* Age-adjusted gender difference significant

Values are number of deaths expressed as a percentage of total number of deaths

AMI: acute myocardial infarction, COPD: chronic obstructive respiratory disease, DM: diabetes mellitus

were not statistically significant (Table 3). The mortality risks at 1-year were similar for men and women (Table 4).

Five-year mortality

Mortality risk at 5-year was 8.3% for men younger than 45 years, 84.2% for men older than 85 years, 1.7% for women younger than 45 years and 74.4% for women older than 85 year (Table 4). The crude overall mortality was higher for men (relative risk 1.31;95% CI 1.03 to 1.25) which persisted after adjustment for potential confounding factors (Table 4).

Discussion

This study provides estimates of absolute short- and long-term risk of death after an initial hospital admission for PAD in the lower extremities. Our findings demonstrate that, although short-term mortality risk after initial admission for PAD in the lower extremities is relatively low, 5-year mortality risk is high, especially in men.

One-year mortality rates were higher in the present study than those reported in intervention studies evaluating the effect of drug treatment for IC [23-25]. In these trials, mortality risks (around 1.2% after 1 year) were much lower than the mortality risk in our study population (mortality risk 10.4% after 1 year). This likely reflects exclusion of the sickest patients from participation in trials [26]. Gender stratified 1-year and 5-years mortality risks (6% and 38% in men and 4% and 20% in women, respectively) that were reported for patients first seen with IC in hospital [5] were also somewhat lower in comparison with our findings, except for 5-years mortality in men. Much higher gender stratified 1-year and 5-years mortality risks (22%

and 67% in men and 17% and 62% in women, respectively) have been reported for patients with CLI [27]. However, comparison between these studies and our study is difficult, as the baseline clinical characteristics of the patients in the present study are mostly unknown.

Whereas studies reporting stratified (for age and/or gender) mortality risks for patients with PAD in lower extremities are scarce, many studies reported mortality risks for PAD patients stratified by ankle-brachial index (ABI) [14,16,28]. These studies indicate that a low ABI is associated with high mortality risk. Five-year mortality risks of 16% and 34% have been reported for patients with ABI 0.71-0.9 and <0.7, respectively [15] and 34% and 56% for patients with ABI 0.4-0.85 and ABI <0.4 [28]. The get-ABI study [29] reported higher risk of death in patients with peripheral disease (low ABI) compared with those without (hazard ratio 2.3), suggesting that ABI may be a good risk predictor beyond conventional risk predictors [30].

The long-term risk of death of patients with a first hospitalization for PAD in the lower extremities is high compared to risk of death in the general population (Figure 1 and Figure 2). Furthermore, comparison with survival after admission for other atherosclerotic diseases such as acute myocardial infarction and ischemic stroke showed similar mortality risks (Figure 1 and Figure 2) [13,18,31]. In contrast, awareness of the severity of PAD in the lower extremities is low as in general population the familiarity with this disease is significantly lower than that for any other cardiovascular disease. A recent study showed that 26% of the public was familiar with the disorder and of

Table 3: Mortality risk at 28 days, 1 year and 5 years after a first hospital admission (1997 or 2000) for PAD in the lower extremities in the Netherlands, by age and gender.

			Men		Women		RR (95% CI) for Men vs Women
	No. of men	No. of women	Age	No. of Deaths	Percentage Deaths	No. of Deaths	
28-day mortality	109	116	< 45	-	-	-	-
	133	95	45-49	-	-	-	-
	236	128	50-54	-	-	3	2.3
	263	116	55-59	-	-	-	-
	322	162	60-64	-	-	-	-
	444	215	65-69	10	2.3	4	1.9 1.21 (0.38-3.82)
	425	285	70-74	6	1.4	3	1.1 1.34 (0.34-5.32)
	363	242	75-79	15	4.1	11	4.5 0.91 (0.42-1.95)
	168	143	80-84	13	7.7	11	7.7 1.0 (0.47-2.18)
	76	117	85+	14	18.4	22	18.8 0.98 (0.54-1.79)
	2,539	1,619	all ages	60	2.4	57	3.5
1-year mortality	109	116	< 45	2	1.8	-	-
	133	95	45-49	3	2.3	-	-
	236	128	50-54	7	3.0	5	3.9 0.75 (0.25-2.34)
	263	116	55-59	7	2.7	3	2.6 1.03 (0.27-3.91)
	322	162	60-64	22	6.8	9	5.6 1.23 (0.58-2.61)
	444	215	65-69	36	8.1	14	6.5 1.25 (0.69-2.26)
	425	285	70-74	50	11.8	23	8.1 1.46 (0.91-2.33)
	363	242	75-79	55	15.2	31	12.8 1.18 (0.79-1.78)
	168	143	80-84	44	26.2	33	23.1 1.13 (0.77-1.68)
	76	117	85+	36	47.7	48	41.0 1.15 (0.84-1.59)
	2,539	1,619	all ages	262	10.3	168	10.4
5-year mortality	109	116	< 45	9	8.3	2	1.7 4.79 (1.06-21.7)
	133	95	45-49	10	7.5	4	4.2 1.79 (0.58-5.52)
	236	128	50-54	21	8.9	11	8.6 1.04 (0.52-2.08)
	263	116	55-59	37	14.1	7	6.0 2.33 (1.07-5.07)
	322	162	60-64	73	22.7	31	19.1 1.18 (0.81-1.72)
	444	215	65-69	136	30.6	53	24.7 1.24 (0.95-1.63)
	425	285	70-74	157	36.9	74	26.0 1.42 (1.12-1.79)
	363	242	75-79	171	47.1	100	41.3 1.14 (0.95-1.37)
	168	143	80-84	108	64.3	74	51.7 1.24 (1.02-1.51)
	76	117	85+	64	84.2	87	74.4 1.13(0.98-1.31)
	2,539	1,619	all ages	786	31.0	443	27.4

- Data about 6 patients (male <65 or women <50 and from 55 to 64 year) were not available as a consequence of privacy regulation

those only 14% was aware that the disease could lead to death [32]. Furthermore, PAD patients tend to be under-treated compared to patients with other manifestations of atherosclerosis and it seems that cardiovascular risk factor management for prevention in PAD patients is very modest [33,34].

Strength of our study is the large size of the cohort obtained from usual care with a large age range and information on both men and women. Even though the validity of national registries has been questioned, several studies have shown that for the Netherlands, the validity is adequate [35,36]. Furthermore a high validity of the linkage between them has been demonstrated [36,37].

We provided detailed information on age- and gender-specific risks, while a large number of publications, including institutional and population-based studies, simply present overall mortality risks of groups of patients without the presentation of the information by age and gender, despite the evidence that mortality depends on age and gender.

Besides age and gender, there are many other factors that may contribute to the prognosis of PAD patients. The stage of PAD, presence of traditional cardiovascular risk factors (e.g. smoking) [38], physical inactivity [39], systemic inflammation [40], impaired renal function [41], hypercholesterolemia, statin use and ABI lower than 0.60

Table 4: Gender differences in short- and long-term mortality after a first hospital admission (1997 or 2000) for PAD in the lower extremities in the Netherlands

PAD in the lower extremities	
	HR (95% CI)*
Crude	
28 days	0.67 (0.47–0.96)
1 year	0.90 (0.81–1.20)
5 years	1.15 (1.03–1.29)
Model I	
28 days	0.85 (0.59–1.24)
1 year	1.17 (0.97–1.43)
5 years	1.36 (1.21–1.53)

Hazard ratio (95% Confidence interval) men vs women.
 Model I: adjusted for age, co-morbidity (previous admissions for cardiovascular disease or diabetes mellitus)

[14] have shown to influence the prognosis of PAD patients. Unfortunately, no information in the registry was available on these factors and therefore there cannot be adjusted for these factors in the analysis of the data. On the other hand, our primary goal was to provide absolute mortality risks stratified by age and gender as absolute risks are easier to interpret and they provide a clear presentation of the size of the burden of disease in these patients, which may be helpful to increase awareness, as it makes the problem as clear as possible.




Figure 1
Mortality risk at 5 years* after a first hospital admission for PAD in the lower extremities, acute myocardial infarction and ischemic stroke, by age. Men *
 Mortality risks AMI, IS and GP extracted from other data [18,31,47] AMI: Acute myocardial Infarction, IS: Ischemic stroke, PAD: Peripheral arterial disease in the lower extremities, GP: General population




Figure 2
Mortality risk at 5 years* after a first hospital admission for PAD in the lower extremities, acute myocardial infarction and ischemic stroke, by age. Women *
 Mortality risks AMI, IS and GP extracted from other data [18,31,47] AMI: Acute myocardial Infarction, IS: Ischemic stroke, PAD: Peripheral arterial disease in the lower extremities, GP: General population

Further aspects of our study that need critical consideration are 1.) the study population is restricted to patients with a first admission for PAD in the lower extremities. Non-hospitalized patients were not included, while those admitted for PAD in the lower extremities are most likely more severe patients compared to those not admitted and may therefore have a higher mortality risk as compared to the entire group of patients with PAD in the lower extremities. 2.) In our data we found a higher percentage of deaths after initial admission for PAD in the lower extremities due to lung cancer and respiratory diseases in men as compared to women. This might be viewed as a higher smoking prevalence among men. Smoking is one of the major risk factors for the development of PAD in the lower extremities [42-44], the prevalence is higher among men [45] and smoking reduces survival in PAD patients [46]. Smoking behaviour might affect our results through overestimation of the gender differences in mortality risk. However, exclusion of the deaths caused by lung cancer and respiratory diseases did not change the gender differences in mortality risk (data not shown). 3.) The limitation of previous admissions to maximal 6 years, might have led to that some "first" patients with PAD in lower extremities were actually recurrent patients with PAD in the lower extremities. These may be more severe patients and on the premise that severity is associated with a higher mortality risk, possibly leading to some overestimation of the mortality risk. The extent of which is difficult to quantify.

Conclusion

Our study provides nationwide estimates of short- and long-term risk of death after an initial hospital admission for PAD in the lower extremities. Our findings demonstrate that, 5-years mortality risk is high, especially in men and comparable to that of patients admitted for acute myocardial infarction or ischemic stroke. Though, in general population the awareness of the severity of PAD in the lower extremities is significantly lower than that for any other cardiovascular disease and it seems that cardiovascular risk factor management for prevention in PAD patients is very modest.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

IV performed the statistical analysis and drafted the manuscript. GB drafted the manuscript. JR participated in the design of this study and commented the draft. AB participated in the design of this study and its coordination. FM conceived of the study and commented the draft. DG conceived of the study and commented the draft. MB conceived of the study, and participated in its design and coordination. All authors read and approved the final manuscript.

Acknowledgements

This study was supported by a grant from the Netherlands Heart Foundation (grant number 31653251). The study was part of the project 'Cardiovascular disease in the Netherlands: figures and facts' of the Netherlands Heart Foundation.

References

- Belch JJ, Topol EJ, Agnelli G, Bertrand M, Califf RM, Clement DL, et al.: **Critical issues in peripheral arterial disease detection and management: a call to action.** *Arch Intern Med* 2003, **163(8)**:884-92.
- Hiatt WR, Regensteiner JG, Hargarten ME, Wolfel EE, Brass EP: **Benefit of exercise conditioning for patients with peripheral arterial disease.** *Circulation* 1990, **81(2)**:602-9.
- Hirsch AT, Haskal ZJ, Hertzner NR, Bakal CV, Creager MA, Halperin JL, et al.: **ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation.** *Circulation* 2006, **113(11)**:e463-e654.
- Dormandy J, Heeck L, Vig S: **The fate of patients with critical leg ischemia.** *Semin Vasc Surg* 1999, **12(2)**:142-7.
- Jelnes R, Gaardsting O, Hougaard JK, Baekgaard N, Tonnesen KH, Schroeder T: **Fate in intermittent claudication: outcome and risk factors.** *Br Med J (Clin Res Ed)* 1986, **293(6555)**:1137-40.
- Fowkes FG: **Epidemiology of atherosclerotic arterial disease in the lower limbs.** *Eur J Vasc Surg* 1988, **2(5)**:283-91.
- Vogt MT, Wolfson SK, Kuller LH: **Lower extremity arterial disease and the aging process: a review.** *J Clin Epidemiol* 1992, **45(5)**:529-42.
- Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al.: **Mortality over a period of 10 years in patients with peripheral arterial disease.** *N Engl J Med* 1992, **326(6)**:381-6.
- Hughson WG, Mann JI, Garrod A: **Intermittent claudication: prevalence and risk factors.** *Br Med J* 1978, **1(6124)**:1379-81.
- McDermott MM, Mandapat AL, Moates A, Albay M, Chiou E, Celic L, et al.: **Knowledge and attitudes regarding cardiovascular disease risk and prevention in patients with coronary or peripheral arterial disease.** *Arch Intern Med* 2003, **163(18)**:2157-62.
- Cacoub PP, Abola MT, Baumgartner I, Bhatt DL, Creager MA, Liao CS, et al.: **Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry.** *Atherosclerosis* 2009, **204(2)**:e86-92.
- Bowlin SJ, Medalie JH, Flocke SA, Zyzanski SJ, Goldbourt U: **Epidemiology of intermittent claudication in middle-aged men.** *Am J Epidemiol* 1994, **140(5)**:418-30.
- Caro J, Migliaccio-Walle K, Ishak KJ, Proskorovsky I: **The morbidity and mortality following a diagnosis of peripheral arterial disease: long-term follow-up of a large database.** *BMC Cardiovasc Disord* 2005, **5**:14.
- Feringa HH, Bax JJ, Hoeks S, van WV, Elhendy A, Karagiannis S, et al.: **A prognostic risk index for long-term mortality in patients with peripheral arterial disease.** *Arch Intern Med* 2007, **167(22)**:2482-9.
- Leng GC, Lee AJ, Fowkes FG, Whiteman M, Dunbar J, Housley E, et al.: **Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population.** *Int J Epidemiol* 1996, **25(6)**:1172-81.
- McDermott MM, Tian L, Liu K, Guralnik JM, Ferrucci L, Tan J, et al.: **Prognostic value of functional performance for mortality in patients with peripheral artery disease.** *J Am Coll Cardiol* 2008, **51(15)**:1482-9.
- Smith GD, Shipley MJ, Rose G: **Intermittent claudication, heart disease risk factors, and mortality. The Whitehall Study.** *Circulation* 1990, **82(6)**:1925-31.
- Koek HL, de BA, Gast F, Gevers E, Kardaun JW, Reitsma JB, et al.: **Short- and long-term prognosis after acute myocardial infarction in men versus women.** *Am J Cardiol* 2006, **98(8)**:993-9.
- Vaartjes I, Reitsma JB, de BA, Berger-van SM, Bos MJ, Breteler MM, et al.: **Nationwide incidence of first stroke and TIA in the Netherlands.** *Eur J Neurol* 2008, **15(12)**:1315-23.
- The International Statistical Classification of Diseases, Injuries and Causes of Death. Ninth Revision.** In *Clinical Modification* Washington DC: U.S. World Health Organization; 1979.
- International Statistical Classification of Diseases and Related Health Problems.** In *Tenth revision* Geneva, World Health Organization; 1992.
- Reitsma JB, Kardaun JW, Gevers E, de BA, van der WJ, Bonsel GJ: **[Possibilities for anonymous follow-up studies of patients in Dutch national medical registrations using the Municipal Population Register: a pilot study].** *Ned Tijdschr Geneesk* 2003, **147(46)**:2286-90.
- Brevetti G, Diehm C, Lambert D: **European multicenter study on propionyl-L-carnitine in intermittent claudication.** *J Am Coll Cardiol* 1999, **34(5)**:1618-24.
- Hiatt WR, Klepack E, Nehler M, Regensteiner JG, Blue J, Imus J, et al.: **The effect of inhibition of acyl coenzyme A-cholesterol acyltransferase (ACAT) on exercise performance in patients with peripheral arterial disease.** *Vasc Med* 2004, **9(4)**:271-7.
- Mohler ER III, Hiatt WR, Olin JW, Wade M, Jeffers R, Hirsch AT: **Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue: a double-blind, randomized, controlled trial.** *J Am Coll Cardiol* 2003, **41(10)**:1679-86.
- Brass EP, Hiatt WR: **Review of mortality and cardiovascular event rates in patients enrolled in clinical trials for claudication therapies.** *Vasc Med* 2006, **11(3)**:141-5.
- Hultgren R, Olofsson P, Wahlberg E: **Gender differences in patients treated for critical limb ischemia.** *Eur J Vasc Endovasc Surg* 2005, **29(3)**:295-300.

28. McKenna M, Wolfson S, Kuller L: **The ratio of ankle and arm arterial pressure as an independent predictor of mortality. *Atherosclerosis* 1991, 87(2-3):19-28.**
29. Diehm C, Lange S, Darius H, Pittrow D, von SB, Tepohl G, et al.: **Association of low ankle brachial index with high mortality in primary care. *Eur Heart J* 2006, 27(14):1743-9.**
30. Diehm C, Darius H, Burghaus I, Mahn M, Pittrow D: **Ankle brachial index vs metabolic syndrome for risk prediction. *Lancet* 2008, 372(9645):1221-2.**
31. Vaartjes I, Reitsma JB, Berger-van Sijl M, Bots ML: **Gender differences in mortality after hospital admission for stroke. *Accepted for publication in Cerebr Dis* 2009.**
32. Hirsch AT, Murphy TP, Lovell MB, Twillman G, Treat-Jacobson D, Harwood EM, et al.: **Gaps in public knowledge of peripheral arterial disease: the first national PAD public awareness survey. *Circulation* 2007, 116(18):2086-94.**
33. Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA: **Patients with peripheral arterial disease in the CHARISMA trial. *Eur Heart J* 2009, 30(2):192-201.**
34. Watson K, Watson BD, Pater KS: **Peripheral arterial disease: a review of disease awareness and management. *Am J Geriatr Pharmacother* 2006, 4(4):365-79.**
35. Mackenbach JP, van Duyn WM, Kelson MC: **Certification and coding of two underlying causes of death in The Netherlands and other countries of the European Community. *J Epidemiol Community Health* 1987, 41(2):156-60.**
36. Paas GRA, Veenhuizen KCW: **Research on the validity of the LMR: [In Dutch]. *Utrecht: Prismant* 2002.**
37. De Bruin A, Kardaun JWPF, Gast A, et al.: **Record linkage of hospital discharge register with population register: experiences at Statistics Netherlands. *Statistical Journal of the United Nations Economic Commission for Europe* 2004, 21:23-32.**
38. Sethi A, Arora RR: **Medical management and cardiovascular risk reduction in peripheral arterial disease. *Exp Clin Cardiol* 2008, 13(3):113-9.**
39. Gardner AW, Montgomery PS, Parker DE: **Physical activity is a predictor of all-cause mortality in patients with intermittent claudication. *J Vasc Surg* 2008, 47(1):117-22.**
40. Reiss AB, Edelman SD: **Recent insights into the role of prostanoids in atherosclerotic vascular disease. *Curr Vasc Pharmacol* 2006, 4(4):395-408.**
41. Pasqualini L, Schillaci G, Pirro M, Vaudo G, Siepi D, Innocente S, et al.: **Renal dysfunction predicts long-term mortality in patients with lower extremity arterial disease. *J Intern Med* 2007, 262(6):668-77.**
42. Ingolfsson IO, Sigurdsson G, Sigvaldason H, Thorgeirsson G, Sigfusson N: **A marked decline in the prevalence and incidence of intermittent claudication in Icelandic men 1968-1986: a strong relationship to smoking and serum cholesterol-the Reykjavik Study. *J Clin Epidemiol* 1994, 47(11):1237-43.**
43. Jensen SA, Vatten LJ, Nilsen TI, Romundstad PR, Myhre HO: **The association between smoking and the prevalence of intermittent claudication. *Vasc Med* 2005, 10(4):257-63.**
44. Meru AV, Mitra S, Thyagarajan B, Chugh A: **Intermittent claudication: an overview. *Atherosclerosis* 2006, 187(2):221-37.**
45. Giskes K, Kunst AE, Benach J, Borrell C, Costa G, Dahl E, et al.: **Trends in smoking behaviour between 1985 and 2000 in nine European countries by education. *J Epidemiol Community Health* 2005, 59(5):395-401.**
46. Khan S, Cleanthis M, Smout J, Flather M, Stansby G: **Life-style modification in peripheral arterial disease. *Eur J Vasc Endovasc Surg* 2005, 29(1):2-9.**
47. **Statline *Statistics Netherlands* 2009 [<http://statline.cbs.nl/statweb/>].**

Pre-publication history

The pre-publication history for this paper can be accessed here:

<http://www.biomedcentral.com/1471-2261/9/43/prepub>

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

